Literature DB >> 23876864

Incidence of pineal gland cyst and pineoblastoma in children with retinoblastoma during the chemoreduction era.

Aparna Ramasubramanian1, Christina Kytasty, Anna T Meadows, Jerry A Shields, Ann Leahey, Carol L Shields.   

Abstract

PURPOSE: To report on the frequency of cysts and tumors of the pineal gland in patients with retinoblastoma.
DESIGN: Observational retrospective case control study.
SETTING: Institutional. study population: Four hundred eight patients treated for retinoblastoma from January 2000 to January 2012 at Wills Eye Institute, Philadelphia, Pennsylvania, USA. OBSERVATION PROCEDURE: Magnetic resonance imaging (MRI) features of the pineal gland were evaluated in all patients with retinoblastoma. Characteristics of patients with pineal cysts and pineoblastoma were reviewed. MAIN OUTCOME MEASURES: Comparison of frequency of pineal gland cyst and pineoblastoma in children managed with systemic chemoreduction vs other methods.
RESULTS: Of 408 patients, treatment included systemic chemoreduction in 252 (62%) and nonchemoreduction methods in 156 (38%). Overall, 34 patients (8%) manifested pineal gland cyst and 4 (1%) showed pineoblastoma. Of all 408 patients, comparison (chemoreduction vs nonchemoreduction) revealed pineal cyst (20/252 vs 14/156, P = .7) and pineoblastoma (1/252 vs 3/156, P = .1). The pineal cyst (n = 34) (mean diameter 4 mm) was asymptomatic (n = 34), followed conservatively (n = 34), and with minimal enlargement (n = 2, 9%) but without progression to pineoblastoma. The cyst was found in 22 germline and 12 nongermline patients (P = .15). Among the 4 patients with pineoblastoma, all had germline mutation and 2 had family history of retinoblastoma. Among all patients with family history of retinoblastoma (n = 45), 2 (4%) developed pineoblastoma. The pineoblastoma was asymptomatic in 2 patients and symptomatic with vomiting and headache in 2 patients. The mean interval from date of retinoblastoma detection to pineal cyst was 2 months (median 2, range 0-8 months) and to pineoblastoma was 27 months (median 28, range 7-46 months). Management included aggressive chemotherapy and radiotherapy, with 2 survivors.
CONCLUSIONS: Pineal gland cyst was incidentally detected in 8% of retinoblastoma patients, causing no symptoms, and without progression to pineoblastoma. Pineoblastoma was detected in 1% of patients and fewer patients who received systemic chemotherapy developed pineoblastoma, possibly indicating a systemic protective effect.
Copyright © 2013 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2013        PMID: 23876864     DOI: 10.1016/j.ajo.2013.05.023

Source DB:  PubMed          Journal:  Am J Ophthalmol        ISSN: 0002-9394            Impact factor:   5.258


  9 in total

1.  Germ-line and somatic DICER1 mutations in pineoblastoma.

Authors:  Leanne de Kock; Nelly Sabbaghian; Harriet Druker; Evan Weber; Nancy Hamel; Suzanne Miller; Catherine S Choong; Nicholas G Gottardo; Ursula R Kees; Surya P Rednam; Liselotte P van Hest; Marjolijn C Jongmans; Shalini Jhangiani; James R Lupski; Margaret Zacharin; Dorothée Bouron-Dal Soglio; Annie Huang; John R Priest; Arie Perry; Sabine Mueller; Steffen Albrecht; David Malkin; Richard G Grundy; William D Foulkes
Journal:  Acta Neuropathol       Date:  2014-07-15       Impact factor: 17.088

2.  A Potential Role For Apparent Diffusion Coefficient in the Diagnosis of Trilateral Retinoblastoma.

Authors:  Sameer Farouk Sait; Sofia Haque; Sasan Karimi; Karim J Rebeiz; Jasmine H Francis; Brian P Marr; David H Abramson; Mark M Souweidane; Ira J Dunkel
Journal:  J Pediatr Hematol Oncol       Date:  2020-04       Impact factor: 1.289

3.  Epidemiological trends in 1452 cases of retinoblastoma from the Surveillance, Epidemiology, and End Results (SEER) registry.

Authors:  Michael T Andreoli; Felix Y Chau; Michael J Shapiro; Yannek I Leiderman
Journal:  Can J Ophthalmol       Date:  2017-07-22       Impact factor: 1.882

Review 4.  Retinoblastoma and Neuroblastoma Predisposition and Surveillance.

Authors:  Junne Kamihara; Franck Bourdeaut; William D Foulkes; Jan J Molenaar; Yaël P Mossé; Akira Nakagawara; Andreu Parareda; Sarah R Scollon; Kami Wolfe Schneider; Alison H Skalet; Lisa J States; Michael F Walsh; Lisa R Diller; Garrett M Brodeur
Journal:  Clin Cancer Res       Date:  2017-07-01       Impact factor: 12.531

Review 5.  Risk definition and management strategies in retinoblastoma: current perspectives.

Authors:  Fariba Ghassemi; Alireza Khodabande
Journal:  Clin Ophthalmol       Date:  2015-06-08

Review 6.  Chemotherapy in Retinoblastoma: Current Approaches.

Authors:  Özge Yanık; Kaan Gündüz; Kıvılcım Yavuz; Nurdan Taçyıldız; Emel Ünal
Journal:  Turk J Ophthalmol       Date:  2015-12-05

Review 7.  Recent advancements in the management of retinoblastoma and uveal melanoma.

Authors:  Amy C Schefler; Ryan S Kim
Journal:  F1000Res       Date:  2018-04-18

8.  Outcomes of neonatal retinoblastoma in pre-chemotherapy and chemotherapy eras.

Authors:  David A Camp; Lauren A Dalvin; Rachel Schwendeman; Li-Anne S Lim; Carol L Shields
Journal:  Indian J Ophthalmol       Date:  2019-12       Impact factor: 1.848

Review 9.  Modern treatment of retinoblastoma: A 2020 review.

Authors:  David Ancona-Lezama; Lauren A Dalvin; Carol L Shields
Journal:  Indian J Ophthalmol       Date:  2020-11       Impact factor: 1.848

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.